Sun Pharma defies volatility with $3.2bn jumbo

Daiichi Sankyo Company has exited India’s Sun Pharmaceutical Industries through a jumbo Rp200bn ($3.2bn) block, pricing one of the largest ever ECM deals in the country. An extensive wall crossing process over the weekend helped pave the way for the transaction, which saw a roaring finish despite turbulent market conditions.